Search for courses or information

Dr Hanieh Khalili

Module leader in Pharmaceutical Science

Biotherapeutics development, formulation, characterisation. Ocular drug delivery., University of East London

Dr Khalili  did her BSc and MSc in Chemistry and Analytical Chemistry in Iran. She then accomplished her PhD after completion of MSc in Drug Delivery at the UCL School of Pharmacy when she earned highest distinction on the MSc course. Her PhD was partially funded by PolyTherics for which the project was designed on PEGylation of antibody fragments (Fabs) using disulphide bridging method. Characterisation, conjugation and modification of several therapeutic antibodies  (such as bevacizumab, trastuzumab, infliximab) were studied during her PhD studied.  Dr Khalili did a postdoc research associate  between UCL School of Pharmacy  and Institute of Ophthalmology working with Profs Steve Brocchini and Sir Peng tee Khaw. The key focus of the post-doc was on development, and formulation of antibody mimetics such as bispecific antibodies and fusion proteins to modulate ocular healing after surgery and to develop dosage forms to inhibit inflammation, angiogenesis and fibrosis generally within the eye.  

Dr Hanieh Khalili

    Module leader in Analytical Chemistry and Pharmaceutical Analysis

    Member of Royal Society of Chemistry (MRSC)

    Academy of Pharmaceutical Science (APS)




    Overview

    Antibody-based medicine including monoclonal antibodies, Fcfusion and scFv development, characterisation and formulation

    Research Fields

    Biotherapeutics formulation and stability determination
    Bispecific antibody mimetic for ocular disease


    Collaborators

    • UEL
    • External
    • test
    • UCL Institute of Ophthalmology
    • Visiting Scientist
      UCL School of Pharmacy

    Research

    Protein Modification by Bis-alkylation

    Christina Picken, Sahar Awwad, Mire Zloh, Hanieh Khalili, and Steve Brocchini. Oct 2020. Elsevier. Chapter 16.

    Comparative thermodynamic analysis in solution of a next generation antibody mimetic to VEGF

    H. Khalili P. T. Khaw, S. Brocchini, Sergey K. Filippov. 2018. RSC advance. 8: 35787.

    A simple and rapid spectrophotometric method for the determination of ultra trace amounts of thallium (III) with 4-(4'-N,N-dimethylaminophenyl) urazole as a new reagent

    Khalili, H., Rafiee, Z., Rezaei, B., Mallakpour, Sh.. 2005. Ann Chim. 897-903.

    Antibody fragments: Prolonging circulation half-life special issue-antibody research

     Herrington-Symes, A.,  Farys, M., Khalili, H., Brocchini, S.. 2013. Advances in Bioscience and Biotechnology . 689-698.

    Anti-TNFa antibody mimetic to treat ocular inflammation

    H. Khalili, R. W. Lee, P. T. Khaw, S. Brocchini, A. Dick, D. Copland. 2016. Scientific Reports-Nature. 6: 36905..

    Invited book; Chemical and genetic modification

    Farys, M. Ginn, C, Badescu, G., Peciak, K, Pawlisz, E., Khalili, H., Brocchini, S.. 2013. Wiley.

    Comparative binding of disulfide-bridged PEG-Fabs

    Khalili, H., Godwin, A., Choi, J., Lever, R., Brocchini, S.. 2012. Bioconjugate Chemistry.  2262-2277.

    Fab-PEG-Fab as a potential antibody mimetic

     Khalili, H., Godwin, A., Choi, J., Lever, R., Khaw, P. T., Brocchini, S. . 2013. Bioconjugate Chemistry. 1870-1882.

    Fc-fusion mimetics

    Khalili, H., Khaw, P. T., Brocchini, S. . 2016. Biomaterials Science.

    PEGylation and its impact on the design of new protein-based medicines

    Ginn, C., Khalili, H., lever, R., Brocchini, S.. 2014. Future Med Chem. 1829-1846.

    Storage stability of bevacizumab in polycarbonate and polypropylene syringes

    H.Khalili, G. Sharma. A. Froome, P.T. Khaw, S. Brocchini. 2015. Nature-eye. 820-827.

    Publications

    Fully funded PhD studentship, H. Khalili,£86,000  (2019); " Bispecific antibody mimetic for ocular inflammation"
    Research funds, UEL,  H. Khalili, £4,000 (2019); "High concentrated antibody mimetic for subcutaneous injection"
    Early Research Career (ERC), H. Khalili, £8,000 (2016); "To Evaluate FpF stability and properties compared to IgGs"
    CIF equipment funding,UCL, H. Khalili, S. Brocchini, £75,000, (2014) To Purchase equipments;
    Research Innovation Fund, H. Khalili, UCL colleagues £10,000 (2013); " in-vivo study of antibody mimetics to treat ocular inflammation"

    Funding

    Biotherapeutics development and formulations



     There is an unmet clinical need to develop the stable antibodybased drug for patient self-administration (subcutaneous) for chronic diseases. The opportunity to make such a stable drug to also have a sustainable drug release profile, could potentially revolutionise healthcare by delivering new medicine with effective treatment of diseases. There are challenges to formulate protein-based drug for subcutaneous administration such as stability and viscosity since high protein concentration required to achieve the subcutaneous dose.
    The main aim of this project is, therefore, to address the instability of protein of interest (such as aflibercept) at high concentrations. Different approaches are taken to address our aims such as lyophilisation method to stabilise proteins, hydrogel-based system for releasing of bioactive drug in a controlled and sustained manner.
    Ocular drug delivery of biologics to the back of the eye is an important and rapidly developing field of research because of their applications in treatment of ocular neovascularisation disease such as age-macular degeneration (AMD) and inflammation (uveitis).
    Most approved antibody therapies are monospecific and are only able to bind to one target epitope. Bispecific therapies can potentially interact with two different targets to provide synergistic effects for greater clinical benefit than monospecific therapies. While there are 3 approved bispecific antibodies for oncology, none has been approved for ocular indication.
    My research group has been working on development of novel bispecific antibody mimetic to treat ocular indications. This is a collaborative research with UCL School of Pharmacy.

    Interests

    Portfolio

    Analytical Chemistry and Pharmaceutical Science

    Module leader for MSc in Pharmaceutical Science;
    Advanced Pharmaceutical Analysis and Quality Control Module leader for BSc in Chemistry;
    Analytical Analysis

    Teaching